Net Income

A funding round reveals a deeper strategy to tackle the healthcare labor crisis and soaring Medicaid costs with tech, data, and a focus on human dignity.

Two French media giants unite to adapt a global bestseller, a bold move showcasing long-term strategy and resilience in a competitive streaming market.

After a costly restatement process, Next Bridge Hydrocarbons shifts its drilling focus. But can a new strategy resolve its unique shareholder crisis?

Attorney Joe Massaro earns a top community-voted award, a testament to a 25-year legacy of client advocacy and trust in a competitive legal market.

A hedge fund's disclosure reveals a puzzling short position and a fresh stock purchase in American Axle, hinting at a high-stakes arbitrage play.

From a Greenland mine to a Romanian refinery, a tech breakthrough is de-risking a vital new source of rare earths for the West's defense and green tech.

Hong Kong's JM Group raised $15M in a wild NYSE debut. We look past the volatility to see what this IPO reveals about global supply chains and risk.

NextNRG's latest healthcare microgrid deal reveals a high-stakes strategy: turning regulatory pressure into long-term, AI-driven recurring revenue.

A new report finds 41% of firms have hired fraudulent candidates, exposing a critical gap between AI threats and outdated corporate defenses.

GoPro is turning user videos into a new revenue stream for the AI economy. Can this bold strategic shift save the company, or will it get lost in the ethical fog?

With a doubled ETH treasury and 'Synthetic Mining' yielding up to 100%, is Republic Technologies creating the blueprint for Web3 corporate finance?

Illumina's new partnership with MyOme targets a $200B healthcare savings prize. But can AI-driven genomics overcome the hurdles to deliver resilient returns?

MMTEC dodged delisting, but a one-year Nasdaq monitor and a history of reverse splits raise questions about its long-term viability on US exchanges.

Massimo Group's new HVAC-equipped electric utility vehicles are more than a comfort upgrade; they represent a strategic bid for the lucrative commercial fleet market.

Adagio Medical lands ex-Medtronic exec Sean Salmon. His mission: drive its novel cryoablation tech to disrupt the competitive cardiac arrhythmia market.

Astellas Pharma's new deal with venture studio Autobahn Labs isn't just a partnership; it's a strategic overhaul of the R&D pipeline. Here's why.

Beyond a simple acquisition, ZenaTech is executing a bold strategy to digitize the American West, transforming old-guard industries with a DaaS network.

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

A Delaware Supreme Court ruling revives a massive liability risk for Loews, extending a seven-year legal battle over its 2018 Boardwalk Pipelines deal.